Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

KaloBios raises $5mm out of potential $15mm debt offering

Executive Summary

KaloBios Pharmaceuticals Inc. (using its Humaneered platform to develop antibodies for Pseudomonas aeruginosa infections, asthma, and cancer) has raised $5mm in the first tranche of a long-term debt financing from MidCap Financial SBIC. The company is required to draw down another $5mm by June 30, 2013, and has the option to borrow an additional $5mm at that time. The loan, which matures on December 31, 2016, carries annual interest of one month LIBOR plus 600 basis points. KaloBios will make interest-only payments from October 1, 2012-January 1, 2014, at which point the biotech will repay the outstanding principle balance in 36 equal monthly installments, plus accrued interest. MidCap has also received a ten-year warrant to buy up to 176.5k Series E preferred shares at $3.40.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies